fda warning letters compounded tirzepatide 2024 2025 Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Compounding Pharmacy Operating Without Control FDA warns Ozempic and Mounjaro

Researchers categorized participants as either early responders (5% or more weight loss by week twelve) or late responders (less than 5% weight loss by week twelve)

Any discussion of future applications is hypothetical and should not be interpreted as human or veterinary use guidance

Medical evaluation may be helpful if: weight gain continues despite lifestyle changes appetite feels difficult to control obesity-related conditions develop weight-loss medication is being considered A specialist can evaluate metabolic health and recommend a personalized treatment plan

PMC 7823251

The standard semaglutide dosing protocol starts at 0.25mg weekly and titrates up to 2.4mg over approximately 16 to 20 weeks